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ABSTRACT
Study objectives were to determine zilpaterol residues in urine and tissues of sheep fed dietary
zilpaterol HCl, at levels commensurate with feed contamination, using common and novel
screening and quantitative analytical methods. Sheep (50.0 ± 2.7 kg) were offered feed
(1.75 kg/d) containing 0.0075 (L), 0.075 (M), or 0.75 (H) mg kg−1 of zilpaterol for 12 days and
were slaughtered with 0-day (L-0, M-0, H-0; n = 4 each) or 3-day (H-3; n = 4) withdrawal periods.
Rapid immunochromatographic assays (ICA) consistently detected urinary zilpaterol (LOD = 1.7
ng mL−1) in L-0 (54.2%), M-0 (96.0%), and the H-0 (100%) treatment groups but only detected
zilpaterol in tissues (LOD ~2.4 ng g−1) from the H-0 group. Advanced MS-based technologies
detected zilpaterol in some, but not all, tissues of M-0, H-0, L-0, and H-3 sheep. Analytical
techniques commonly used to ensure compliance with show-animal rules, import/export guide-
lines, and regulatory statutes routinely detected residues in animals exposed to zilpaterol at
doses insufficient to elicit growth responses.
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Introduction
Zilpaterol HCl is a β-adrenergic agonist labelled
for inclusion in cattle feed to increase the rate of
weight gain, improve feed efficiency, and increase
carcass leanness during the last 20 to 40 days on
feed (Merck 2018). Although specifically labelled
for cattle, zilpaterol causes growth and leanness-
enhancing effects in small ruminants including
goats (López-Carlos et al. 2014; Hatefi et al.
2017) and sheep (López-Carlos et al. 2010; Brand
et al. 2013; Macías-Cruz et al. 2013). In contrast to
ractopamine HCl, another β-agonist feed additive
used in ruminants, the efficacy of zilpaterol in
non-ruminant species such as swine, chickens,
turkeys, horses, humans, and siluriformes has not
been published. Nevertheless, the assumption that
zilpaterol affects growth and/or body composition,
and may enhance athletic performance or compe-
titive advantage, has caused a multitude of com-
petition organizations to ban zilpaterol completely
in animals and humans (ARCI 2018; HLSR 2018;
WADA 2018). Additionally, zilpaterol is banned
for use in beef and other food-animal species by
most countries (Centner et al. 2014) and, conse-
quently, zilpaterol in edible tissues of any species
is considered violative by numerous international
regulatory agencies.
Several zilpaterol violations have been docu-
mented in show, performance, and food animals
worldwide (Chung and Waters 2013; Hung et al.
2013; Bergin 2014; CHRB 2014). Assays used to
determine violative residues depend upon the
enforcement agency and may vary with respect
to method sensitivity. For banned substances,
including zilpaterol, the presence of any residue,
no matter how low the concentration, may result
in punitive measures (HLSR, Houston Livestock
Show and Rodeo 2018; NWSS 2018). Thus, the
sensitivity of a given assay, not the nature of an
exposure event (purposeful or accidental), may
determine whether a given sample contains viola-
tive residues. To illustrate, Smith et al. (2016)
demonstrated that sheep exposed to ultra-low
levels of dietary ractopamine (10 ng per kg body
weight (bw) per day; 0.5 µg per sheep per day)
excreted sporadically detectable urinary
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ractopamine using quantitative LC-MS/MS meth-
ods. Sheep dosed with 94 ng kg−1 bw per day (5 µg
d−1) of ractopamine-excreted urine in which rac-
topamine residues were typically detected using
both qualitative screening and quantitative analy-
tical methods. That is, state-of-the-art detection
methods were of sufficient sensitivity to detect
exposures to ractopamine hundreds of times less
than doses of ractopamine required to elicit
growth effects in livestock (i.e., about 5 mg kg−1
of feed). Further, detection of ractopamine in
urine, but not tissues, occurred in swine fed com-
plete rations containing 3.8 to 11.2 µg kg−1 of diet;
the source of ractopamine in the ration was
through the inclusion of commercial meat and
bone meal (Aroeira et al. 2019).
The detection of sub-therapeutic levels of animal
feed additives in non-treated animals has practical
consequences. For example, inadvertent β-agonist
contamination of feeds has been claimed (Bergin
2014; CHRB 2014), or documented (Scheidegger
2013; RMTC 2016), in several cases in which β-
agonist residues weremeasured in animals originally
thought to have been illegally treated. Punitive mea-
sures for the illegal treatment of food or competitive
animals can be severe and legal costs can be signifi-
cant. To date, few studies have correlated actual
animal exposure levels with the practical detection
of residues using routinely tested matrices and com-
monly used screening or determinative analytical
methods. For β-agonist compounds, minimum
doses (see discussions by Smith 1998; Smith et al.
2016) are required to elicit clinical or growth pro-
moting effects, so there is no performance or eco-
nomic incentive to expose animals below such doses.
Analytical methods used to enforce policies against
therapeutic or growth effects are typically sensitive
enough to detect animal exposures well below doses
labelled for production purposes.
The objectives of this study were to determine
levels of dietary zilpaterol HCl, below which
growth effects could be expected, but which
might return positive responses by screening and
determinative analytical methods. Because the
detection of illicit drug residues in practice is
based on a variety of screening and confirmatory
analytical methods, we measured residues using
immunochromatographic rapid screening assays
(Shelver and Smith 2018), quantitative ELISA
(Shelver and Smith 2006; Shelver et al. 2010),
UPLC-MS/MS, and relatively recent rapid mass
spectrometric-based detection methods including
atmospheric solid analysis probe (ASAP;
Chakrabarty et al. 2018) and electrospray ioniza-
tion inlet mass spectrometry (ESII-MS; Pagnotti
et al. 2012; Fenner et al. 2017). These instrumental
methods are typical of the range of established
(ELISA; UPLC-MS/MS) and emerging (ASAP,
ESII-MS) sensitivities and specificities of assays
used by regulatory, import/export, show-animal
and animal competition officials.
Materials and methods
Chemicals
Absolute ethanol (USP-grade) was purchased from
Warner-Graham (Cockeysville, MD). Zilpaterol
HCl was extracted from Zilmax® Type A Medicated
Article (4.8% on ground corncob, surfactant, and
binder) and recrystallized in ethanol as described
in the supplementary material of Chakrabarty et al.
(2018). A chemical purity of at least 98% was deter-
mined by the absence of non-assigned protons and
carbons in 1H- and 13C-NMR spectra of recrystal-
lized zilpaterol. Zilpaterol-d7, used as an internal
standard, was purchased from Toronto Research
Chemicals (Toronto, Ontario, Canada).
Study overview
Sheep were fed dietary zilpaterol HCl once daily for
12 consecutive days at levels of 0, 0.0075 (L), 0.075
(M), and 0.75 (H) mg of zilpaterol per kg of feed.
Sheep receiving the L (n = 4) and M (n = 4) treat-
ments were slaughtered with a 0-day withdrawal
period. The H treatment level was fed to two sets of
four sheep each, one set was killed with a 0-day
withdrawal period (H-0), and one set killed with
a 3-day withdrawal period (H-3). All treatments
were provided in 1.75 kg of supplement per day
so that the theoretical exposure of individual sheep
was equivalent to 0.013, 0.13, and 1.3 mg of zilpa-
terol HCl per day for the L-0, M-0, and H-0 and
H-3 treatments, respectively. For comparison, the
approved zilpaterol HCl dosage for cattle is 7.5 mg
kg−1 of feed (90% dry matter; Zilmax® label, Merck
Animal Health, Madison, NJ) equivalent to a daily
exposure of 60 mg per day for a growing beef
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animal eating 8 kg per day. A low end ‘growth’ dose
for sheep is 0.15 mg kg−1 bw (Estrada-Angulo et al.
2008; Rodea et al. 2016), or roughly 7.5 mg day−1
for a 50 kg animal. Feed (1.75 kg) was provided at
approximately 0730 h daily and single, point-in-
time urine samples were collected from animals
on study days 0, 2, 4, 6, 8, 10, and 12 for the
L-0, M-0, and H-0 sheep and on withdrawal days
1, 2, and 3 for the H-3 sheep. Urine was collected at
approximately 0900 on each collection day. Daily
urine samples were analysed for zilpaterol by lat-
eral-flow screening assay at collection and by quan-
titative ELISA, UPLC-MS/MS, and ASAP-MS/MS
after freezing. Skeletal muscle, liver, kidney and
lung extracts were analysed for zilpaterol HCl by
lateral flow assay, ELISA, UPLC-MS/MS, ASAP-
MS/MS, and ESII-MS/MS.
Experimental design
Treatments were each replicated once during four
trials resulting in a total of four animals per treat-
ment. The H treatment (0.75 mg zilpaterol HCl
per kg feed) was comprised of two sets of four
sheep each. One set of animals was slaughtered
with a 0-day withdrawal period (H-0), and the
other set was slaughtered after a 3-day withdrawal
period (H-3). Four pens (3.0 × 3.4 m) within the
Biosciences Research Laboratory barn facility were
assigned a zilpaterol treatment level, and a single
wether lamb per trial was randomly assigned to
treatment. Treatments were not randomized across
pens between trials to minimize the probability of
across-trial zilpaterol contamination. Two control
animals served as donors for urine and tissues,
these animals were housed separately, but in the
same facility, as the zilpaterol-treated sheep.
Test animals
A study protocol was approved by the local USDA
ARS Institutional Animal Care and Use Committee
prior to the purchase of research animals. Wether
sheep (n = 18) were purchased from the North
Dakota State University sheep flock and transported
approximately 3 km to the USDA barn facility. Each
sheep was uniquely identified by ear tag at arrival,
and all animals were adapted to the barn facility for
a minimum of 7 d prior to the initiation of the study
protocol with ad libitum access to alfalfa/grass hay
and water. During the adaptation period, sheep were
trained to eat through head gates by allowing access
to 1.75 kg of control ration per day. Control ration
was pelleted and was composed of soy hulls (25.6%),
salt (0.6%), ammonium chloride (0.6%), limestone
(1.9%), vitamins A, D, and E (0.01%, 0.03%, and
0.06%, respectively), dry molasses (3.1%), thiamine
(0.01%), decox (0.03%), and ground corn (68.0%).
On adaptation days 6 and 7 head gates were closed at
approximately 0900 h and sheep were held until
micturition occurred (typically less than 1.5 h).
Urine was collected into 400 mL polypropylene bea-
kers as described by Smith et al. (2016).
Feed preparation
A 1 mg mL−1 stock solution of zilpaterol HCl was
prepared by dissolving 200 mg of zilpaterol HCl in
absolute ethanol within a 200 mL volumetric flask.
The flask was capped, sealed with Parafilm, and
mixed by inversion a minimum of 10 times. Three
levels of zilpaterol containing feed were prepared. To
prepare feed containing 0.0075mg of zilpaterol per kg
of feed, 0.675 mL of the zilpaterol HCl stock solution
was transferred to a 500 mL volumetric flask contain-
ing about 200 mL of absolute ethanol and the flask
was diluted to the mark with absolute ethanol. The
contents of the flask were transferred to a no-dead
volume plastic spray bottle, and the ethanolic zilpa-
terol solution was sprayed onto 90 kg of sheep feed as
it mixed within a Davis mixer. After the addition of
the entire contents of the spray bottle onto feed (over
about a 15-min period), sequential 25mL additions of
clean ethanol were added to the spray bottle, and the
rinses were sprayed onto the feed. Prepared feed was
transferred from the Davis mixer and spread onto
plastic tarpaulins within a confined, concrete-floored
animal facility to allow drying for a minimum of 12
h. After drying, 1.75 kg aliquots of feed were weighed
into labelled plastic zipper bags and stored until use at
−20°C. Feed containing 0.075 mg kg−1 of zilpaterol
HCl was prepared in the same manner except that
500 mL of working ethanolic solution was prepared
by transferring 6.75 mL of the zilpaterol HCl stock
solution to a 500mL volumetric flask. The contents of
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the working solution were transferred to 90 kg of feed
as described. Two treatments (H-0 and H-3) were
based on a dose of zilpaterol at 0.75 mg kg−1 feed.
Therefore, a total of 180 kg of feed containing 0.75mg
of zilpaterol HCl per kg of feed was prepared as
described except that 135 mL of the stock solution
was transferred to a 1 L volumetric flask and diluted
to the mark.
Study period
Two control sheep were maintained throughout the
live phase of the study (May through August 2017).
During each of the four trials, 12 urine samples
were collected from the control sheep for a total
of 48 samples per control sheep for the study. The
large number of control samples was used to assess
the propensity of a newly developed zilpaterol
immunochromatographic assay (ICA) for return-
ing false-positive results (Shelver and Smith 2018).
Wethers were provided ad libitum access to grass/
alfalfa hay, and water and zilpaterol treatments
were provided in 1.75 kg allotments of test feed at
approximately 0730 h daily (Study days 0 to11) for
12 consecutive days. Feeding and sample collection
was essentially identical to that described by Smith
et al. (2016) with the exception that pre-dose sam-
ples were collected from each sheep prior to the
initiation of zilpaterol HCl exposures. The first
post-dosing urine sample was collected on
Study Day 0 within an hour or two of zilpaterol
exposure. Aliquots of urine were analysed by ICA
on-site or were frozen (−20°C or less) until chemi-
cal analysis. On study Day 12 (withdrawal day 0),
feed pans were removed from animals approxi-
mately 2 h prior to euthanasia. Sheep were eutha-
nized using a captive bolt stun gun followed
immediately by exsanguination. Sheep slaughtered
after a 3-day withdrawal period was provided
access to control ration (1.75 kg) on each of with-
drawal days 0, 1, and 2 and were euthanized on
withdrawal day 3, approximately 72 h after the last
exposure to zilpaterol containing feed. At slaughter
the semitendinosus muscle, lung, liver, and kidneys
were removed, cut into 1 to 2 cm3 pieces, aliquoted,
and frozen (−20°C or less) until analysis.
Sample analysis
Immunochromatographic analysis
At collection, each urine sample was assayed by
a zilpaterol-specific ICA which has a 90% positive
zilpaterol detection limit of 1.7 ngmL−1 (Shelver and
Smith 2018). Briefly, 160 µL aliquots of fresh urine
were directly applied to the sample pads of immu-
nochromatographic strips, and a 10-min develop-
ment time was allowed before analyst interpretation.
The presence of zilpaterol was indicated by reduced
colour intensity or elimination of the test line. Each
test was scored as zilpaterol ‘negative’ or ‘positive’ by
two independent scorers, blinded with respect to
sample identity, and results were autonomously
recorded. Test strip viability was controlled with
the use of a control line (Shelver and Smith 2018);
if the control line was absent on a given test strip, the
test was considered invalid and was repeated with
another test strip. All daily sample assays were con-
currently run with both positive (4 ng mL−1) and
negative control urine samples.
Quantitative enzyme-linked immunosorbent assay
Competitive inhibition immunoassays were con-
ducted essentially as described by Shelver and
Smith (2006). Briefly, samples or matrix matched
standards were added to a zilpaterol-butyrate
bovine serum albumin coated 96-well plate and co-
incubated with zilpaterol antibody. After 90 min,
the unreacted reagents were washed off the plates
using PBS-Tween, and horseradish peroxidase-
labelled anti-mouse IgG was subsequently added.
Substrate (3,3ʹ,5,5ʹ-tetramethylbenzidine) was used
to generate signal and plates were read at 450 nm.
The calibration curve used for urine contained
points at 0, 0.05, 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50,
100, and 1000 ng mL−1 while tissue standard curves
were comprised of 0, 0.2, 0.5, 1, 2, 5, 10, and 20 ng of
zilpaterol per mL. A four-parameter logistic equa-
tion was used to fit the calibration curves, and
unknown zilpaterol concentrations were extrapo-
lated from the linear portion of the curves. Limits of
detection were defined as the concentration that
produced 10% inhibition of antibody binding
while the limits of quantitation were defined as the
concentration that produced 20% of inhibition.
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Quantitative UPLC-MS/MS
Urinary zilpaterol was extracted in preparation for
LC-MS/MS as described by Shelver et al. (2010), but
quantification was based on zilpaterol-d7 internal
standardization. Briefly, a matrix-matched standard
curve containing 0, 0.1, 0.2, 1, 2, 10, 20, and 100
ng mL−1 of zilpaterol and 2 ng mL−1 of zilpaterol-d7
was prepared; the matrix-matched standard curve
was extracted as described by Shelver et al. (2010).
Sample sets always included pooled control urine,
pooled control urine fortified with internal standard
(2 ng), pooled control urine fortified with internal
standard (2 ng) and 4 ng of zilpaterol, and test urine
samples fortified with 2 ng of internal standard.
A Waters Acquity Ultra Performance Liquid
Chromatograph interfaced with aWaters triple quad-
rupole mass spectrometer (Waters, Milford, MA) was
used for mass spectrometric analysis of urine and
tissue samples. Urine samples were prepared for LC-
MS/MS analysis using the solid phase extraction
(SPE) procedure described by Shelver et al. (2010).
A minor modification in cone voltage (40 V) was
used, and the collision energies for the transitions
of m/z 244 (M-OH)+→ 202, 244→ 185 and 244→
157 were 15, 20 and 30 V, respectively. Tissues were
extracted as described by Shelver and Smith (2006)
except that a zilpaterol-d7 internal standard was
employed. Tissue sample sets included tissue blanks,
tissue blanks fortified with an internal standard for-
tified tissue samples (equivalent to 4 ng g−1), and test
tissue samples; the internal standard was added to
tissues prior to extraction at a level of 2 ng g−1.
Tissue extracts were analysed by LC-MS/MS using
the conditions described for urine.
The method limits of detection (LOD) and quan-
tification (LOQ) for zilpaterol in urine were set at 0.5
and 1.0 ng mL−1 commensurate with the two lowest
matrix-matched zilpaterol standards that were reli-
ably detected and quantified. In order for a sample to
qualify as having detectable or quantifiable zilpaterol
residues, each sample duplicate had to contain resi-
dues above the respective LOD or LOQ. Across
urine sample aliquots that had quantifiable (>1
ng mL−1) zilpaterol residues, the average within
sample relative standard deviation was 5.0 ± 6.1%
(n = 109). Across 27 sample sets, analytical recovery
of zilpaterol fortified into control urine at a 20
ng mL−1 level was 99.1 ± 10.6%.
Atmospheric solids analysis probe (ASAP)-MS/MS
Atmospheric pressure mass spectrometric screening
and semi-quantitative analysis of tissues were con-
ducted exactly as described by Chakrabarty et al.
(2018) using an ASAP probe manufactured
by M&M Mass Spec Consulting, LLC (Hockessin,
DE). Tissues were prepared by simple acetonitrile
extraction followed by centrifugation (Chakrabarty
et al. 2018). Mass spectrometric analyses were per-
formed on a Thermo Scientific TSQ Quantum mass
spectrometer (Thermo Fisher Scientific, San Jose,
CA, USA).
Electrospray ionization inlet (ESII)-MS/MS
ESII-MS/MS techniques were based on conditions
described by Pagnotti et al. (2012) and Fenner et al.
(2017). Sample extracts used for analysis were the
same as those used for the UPLC-MS/MS analyses,
except that the extracted samples were stored frozen
(−20 ⁰C or less) until analysis. Shelver and Smith
(2018) previously demonstrated the stability of zilpa-
terol in biological samples for up to 7 years when
stored at −20 ⁰C. A Thermo Scientific TSQ
Quantum mass spectrometer (Thermo Fisher
Scientific, San Jose, CA, USA) interfaced with
a DIONEX UltiMate 3000 liquid chromatograph
(Thermo Fisher Scientific, San Jose, CA, USA) was
used for the analyses. The IonMax source from TSQ
Quantumwas removed and anMSTM,LLC (Newark,
DE) multifunctional ionization platform was used for
running the samples in ESII mode. For ESII, 3 kVwas
applied on a metal union linking the tubing from the
LC with a fused silica tube (75 μm ID × 375 μm OD
from Waters, USA). The other end of the silica tube
was placed ~0.5 to 1mmdeep into the heated (350°C)
ion transfer capillary inlet tube of the TSQ Quantum
mass spectrometer. A solvent system composed of 1:1
of 5%methanol in 0.2% aqueous formic acid and 10%
acetonitrile in 0.2%methanolic formic acid flowing at
50 µL min−1 was used for the analysis of all samples.
No column was used to effect chromatographic
separation and zilpaterol was eluted in the solvent
flow at approximately 0.85 min after injection.
A collision energy of 30 V was used to fragment the
molecular ion (m/z 262 of zilpaterol) to the product
ion m/z 185 in the selected reaction monitoring
(SRM) mode for quantitation. Zilpaterol standards
FOOD ADDITIVES & CONTAMINANTS: PART A 1293
were prepared in blank tissue matrices at 0.1, 0.5, 1, 5,
10, and 20 ng mL−1.
Statistical analyses
Descriptive statistics were calculated using Microsoft
Excel 2010 and/or GraphPad Prism version 7.03 for
Windows (GraphPad Software, La Jolla California
USA). An outlier value in the LC-MS/MS analysis of
the 0.0075 mg kg−1 feed treatment urine samples was
identified using the Grubb’s test (α = 0.001) within
GraphPad Prism Software.
Results
Animal exposures
Table 1 shows target doses, animal weights, final
weights, and zilpaterol intakes. Zilpaterol doses
consumed by sheep on a mass basis (mg of zilpa-
terol per day) were 100%, 93%, 82%, and 86% of
offered doses for the L-0, M-0, H-0 and H-3
treatments, respectively. When doses were calcu-
lated on a body weight basis (Table 1) the middle
dose was 9.6 times that of the low dose, and about
1/10th that of the high dose. Consequently, the
actual doses received by each treatment level
were separated by an order of magnitude, which
was the intent at the inception of the study.
Detection of zilpaterol using an
immunochromatographic assay
Table 2 shows the detection of zilpaterol in sheep
urine by a lateral flow immunoassay having a 90%
detection limit of 1.7 ng mL−1 in sheep urine (Shelver
and Smith 2018). Of the 96 control samples, two
(2.1%) tested positive by lateral flow; of the 44 total
pre-dose urine samples assayed, two tested positive
(4.5%). Overall, of 140 control or pre-dose samples,
four tested positive by immunochromatographic
assay, corresponding to a 2.9% false-positive rate.
Positive immunochromatographic detections were
clearly dose-related with the L-0, M-0, and H-0/H-3
zilpaterol treatments returning 54.2%, 96%, and 100%
positive screening assays, respectively, during the
feeding period. As might be expected, the detection
of zilpaterol in urine by the immunochromatographic
screening assay decreased sequentially with
withdrawal day for the H-3 sheep; that is, 24 h after
withdrawal, zilpaterol was detected in 100% of the
urine samples, but only 50% and 25% of the samples
Table 1. Target and actual zilpaterol HCl exposure levels (means ± standard deviations).
Zilpaterol Offered Weights Zilpaterol Intake
level dose Animals Starting Ending Massa Body Wt.b
mg kg−1 feed mg d−1 n kg kg mg d−1 μg kg−1∙d−1
0.0075 0.013 4 50.3 ± 3.1 53.4 ± 3.2 0.013 ± 0.001 0.25 ± 0.06
0.075 0.131 4 50.7 ± 2.9 53.6 ± 2.5 0.122 ± 0.011 2.4 ± 0.2
0.75–0 D 1.313 4 49.3 ± 1.7 52.6 ± 1.8 1.08 ± 0.12 21.1 ± 1.6
0.75–3 D 1.313 4 50.1 ± 3.6 52.8 ± 3.3 1.13 ± 0.09 22.0 ± 0.5
aActual mass of zilpaterol consumed per day was calculated as the product of the daily dose and the actual amount of zilpaterol containing feed minus orts
(mg kg−1 feed * [kg offered – kg orts] = mg consumed).
bZilpaterol intake on a body weight basis was calculated using an average wt. calculated from the starting and ending body weights.
Table 2. Detection of zilpaterol residues in sheep urine by immunochromatographic rapid screening assay.
Zilpaterol Zilpaterol Intake Rapid Screen Results
Treatment Mass BW (-) (+) Total (-) (+) Total
mg kg−1 feed mg d−1 μg kg−1∙d−1 Period n n n % % %
Control 0 0 94 2 96 97.9 2.1 100
0.0075 0.013 0.25 Pre-dosea 11 1 12 91.7 8.3 100
Dose 11 13 24 45.8 54.2 100
0.075 0.122 2.4 Pre-dose 11 0 11 100 0 100
Dose 1 24 25 4 96 100
0.75–0 D 1.08 21.1 Pre-dose 9 1 10 90 10 100
Dose 0 26 26 0 100 100
0.75–3 D 1.13 22.0 Pre-dose 11 0 11 100 0 100
Dose 0 25 25 0 100 100
Withdrawal D1 0 4 4 0 100 100
Withdrawal D2 2 2 4 50 50 100
Withdrawal D3 3 1 4 75 25 100
aPre-dose samples were collected on two days prior to dosing and on the day of dosing (D0) immediately after making zilpaterol containing feed available. Day 0
samples that tested (+) by the immunochromatographic screen and which also tested positive by LC-MS/MS were not included in the pre-dose tally.
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at 48 and 72 h after last zilpaterol exposure tested
positive (Table 2).
Quantification of zilpaterol in urine and tissues
Figures 1A and 1B show the excretion of zilpaterol
in the urine of L-0, M-0 (Figure 1B) and H-0 and
H-3 dose animals (Figure 1A) as measured by LC-
MS/MS and quantitative ELISA. Across dosing
days 2 to 12, corresponding to the period when
sheep were actively exposed to dietary zilpaterol,
the average urinary zilpaterol concentrations mea-
sured by UPLC-MS/MS were 2.8 ± 1.0, 21.4 ±
10.0, and 218 ± 92 ng mL−1 for the L, M, and
H doses, respectively. Of note, urinary zilpaterol
concentrations accurately reflected the order of
magnitude difference in dosing. For the L-0
sheep, all urine samples collected on days 2, 4, 6,
8, 10, and 12 contained ELISA and UPLC-MS/MS
quantifiable zilpaterol residues. Urinary zilpaterol
as measured by ASAP-MS/MS, a very rapid, semi-
quantitative mass-spectrometric screening method
(Chakrabarty et al. 2018) returned zilpaterol con-
centrations that were consistent with concentra-
tions returned by ELISA or UPLC-MS/MS, but
which required less than a minute total analysis
time per sample. It should be noted that data
shown in Figure 1b reflect the removal of
a single datapoint (Day 4 of Trial 4, L-0 treatment)
which was deemed to be an outlier by the Grubb’s
test (72.7 and 64.9 ng mL−1 by ELISA and UPLC-
MS/MS, respectively; α = 0.001). The high residue
concentrations in this sample almost certainly
reflect contamination rather than a physiologic
event within the wether because no other samples
from that animal or within the treatment group,
contained residues greater than 5.1 ng mL−1.
Table 3 shows tissue residues of zilpaterol as
assessed by ICA screen (about 10 min analysis
time), ELISA (about 5 h to analyse 40 samples in
Figure 1. Figure 1. Urinary excretion of zilpaterol as assessed by quantitative ELISA (solid black lines), UPLC-MS/MS (dotted lines),
and ASAP-MS (solid grey lines). Panel A, zilpaterol concentrations (ng mL-1) in urine of sheep dosed with 0.75 mg kg-1 of dietary
zilpaterol (triangles) and slaughtered with either 0- (n = 4) or 3-day withdrawal periods (n = 4). Panel B, zilpaterol concentrations in
urine of sheep dosed with 0.075 (squares; n = 4) or 0.0075 mg kg-1 (circles; n = 4) of dietary zilpaterol and slaughtered with a 0-d
withdrawal period and assayed using ELISA (solid black lines), UPLC-MS/MS (dotted lines), or ASAP-MS (solid grey lines).
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parallel), and by UPLC-MS/MS which can easily
extend to over 8 h depending upon the number of
samples run and the degree of processing required.
We used the samples processed for UPLC-MS/MS to
analyse zilpaterol by ESII-MS/MS and were able to
obtain an approximate order of magnitude increase
in sensitivity relative to UPLC-MS/MS. A hyphenated
mass spectrometricmethod, ASAP, requiredminimal
sample preparation; tissue samples (~100 mg) pre-
pared for ASAP-MS/MS were extracted with 200 µL
of ice-cold acetonitrile followed by simple centrifuga-
tion (Chakrabarty et al. 2018).
Zilpaterol residues were not detected in any
tissues of sheep provided the L-0 treatment by
conventional assays such as ICA, ELISA, or
UPLC-MS/MS. Emerging mass-spectral based
methods including ASAP-MS/MS and ESII-MS
/MS were able to detect and/or quantify residues
in kidney, liver, and lung from some L-0 animals,
with the exception of muscle, with ESII-MS/MS
having the greater sensitivity for most tissues
(Table 3). Zilpaterol residues were always detect-
able by ICA screen of liver, kidney, or lung of H-0
animals, but only in one-half of the skeletal muscle
samples. In contrast, the use of quantitative
ELISA, UPLC-MS/MS, ASAP-MS/MS, and ESII-
MS/MS was always useful for detecting and quan-
tifying zilpaterol residues in tissues of H-0 sheep.
A 3-d withdrawal period, however, was sufficient
to reduce tissue residues in H-3 sheep to non-
detectable levels for all methods except ASAP-
MS/MS and ESII-MS/MS.
Table 3. Tissue residues of zilpaterol in sheep receiving feed containing 0.0075, 0.075, and 0.75 mg kg−1 of zilpaterol HCl for 12
consecutive days and slaughtered with either a 0- or 3-day withdrawal period. Residues were detected using a rapid on-site
screening assay (<10-min analysis time), a rapid quantitative ELISA assay (<5 hr analysis time), or a laboratory-based quantitative
assay (>8 hr). A “+” or “-” indicates a positive or negative result from the rapid immunochromatographic screening assay; a tilde (~)
indicates difficult scoring of the immunochromatographic screening assay. Data are shown by individual sheep, separated by
a comma with a sequential presentation of individual animals consistent across the analytical method.
Zilpaterol Analytical Method
Treatment ELISAb UPLC-MS/MS
c ASAP-MS/MSd ESII-MS/MSe
mg kg−1 feed ICAa ng g−1 ng g−1 ng g−1 ng g−1
-Skeletal muscle-
L-0, 0.0075 -, -, -, - NDf ND ND ND
M-0, 0.075 -, -, -, - ND >LOD ND >LODg
H-0, 0.75 ~, +, +, ~ 1.1 ± 0.0 1.3 ± 0.1 8.5 ± 1.8h 1.1 ± 0.1
H-3, 0.75 -, -, -, - ND ND ND ND
-Liver-
L-0, 0.0075 -, -, -, - ND ND ND 0.2 ± 0.1g
M-0, 0.075 -, -, -, - ND >LOD 1.9 ± 0.1g 0.3 ± 0.1
H-0, 0.75 +, +, +, + 1.9 ± 0.2 3.6 ± 0.5 4.0 ± 2.1 3.4 ± 0.1
H-3, 0.75 -, -, -, - ND ND ND > LODg
-Kidney-
L-0, 0.0075 -, -, -, - ND ND ND >LOD
M-0, 0.075 -, ~, -, ~ 0.4 ± 0.1 >LOD 0.6 ± 0.3g 0.4 ± 0.05
H-0, 0.75 +, +, +, + 2.4 ± 0.3 4.4 ± 0.3 2.4 ± 1.7 4.0 ± 0.4
H-3, 0.75 -, -, -, - ND ND ND >LOD
-Lung-
L-0, 0.0075 -, -, -, - ND ND ND >LODh
M-0, 0.075 -, -, -, - ND >LOD ND 0.3 ± 0.1
H-0, 0.75 +, +, +, + 1.2 ± 0.1 2.0 ± 0.1 1.9 ± 1.0g 1.8 ± 0.1
H-3, 0.75 -, -, -, - ND ND ND 0.3 ± 0.2h
aImmunochromatographic assay; muscle LOD, 2.4 ng g−1. LODs for liver, kidney, and lung were not determined.
bEnzyme linked immunosorbent assay; muscle LOD = 0.36 ng g−1, LOQ = 0.54 ng g−1; liver LOD = 0.20 ng g−1, LOQ = 0.34 ng g−1; kidney LOD = 0.18 ng g−1,
LOQ = 0.30 ng g−1; lung LOD = 0.15 ng g−1, LOQ = 0.25 ng g−1.
cUltraperformance liquid chromatography-mass spectrometry; muscle LOD = 0.1 ng g−1, LOQ = 1.0 ng g−1; liver LOD = 0.20 ng g−1, LOQ = 1.0 ng g−1; kidney
LOD = 0.2 ng g−1, LOQ = 1.0 ng g−1; lung LOD = 0.2 ng g−1, LOQ = 1.0 ng g−1.
dAtmospheric Solid Analysis Probe MS; muscle LOD = 0.2 ng g−1, LOQ = 0.6 ng g−1; liver LOD = 0.3 ng g−1, LOQ = 1.1 ng g−1; kidney LOD = 0.1 ng g−1, LOQ
= 0.4 ng g−1; lung LOD = 0.4 ng g−1, LOQ = 1.2 ng g−1.
eElectrospray ionization inlet (ESII) MS; muscle LOD = 0.02 ng g−1, LOQ = 0.1 ng g−1; liver LOD = 0.06 ng g−1, LOQ = 0.1 ng g−1; kidney LOD = 0.03 ng g−1,
LOQ = 0.1 ng g−1; lung LOD = 0.03 ng g−1, LOQ = 0.1 ng g−1.
fND, not detected.
gAverage of two data points, two sheep were ND.
hAverage of three data points, one sheep was ND.
1296 D. J. SMITH ET AL.
Discussion
The presence of zilpaterol residues in competitive
livestock (HLSR, Houston Livestock Show and
Rodeo 2018; NWSS 2018), horses and dogs
(ARCI 2018), and humans (WADA 2015, 2018)
are strictly banned. Nevertheless, numerous alle-
gations of doping have occurred after urine or
tissues of animals (Scheidegger 2013; Bergin
2014; CHRB 2014) have tested positive for zilpa-
terol. Regardless of the class of animal, allegations
of “doping” typically carry severe consequences
including possible suspension of animals, fining,
and/or banning of trainers or owners from the
future competition (ARCI 2018; NWSS 2018). If
legal proceedings are initiated, costs for counsel
and laboratory analyses are typically borne by the
accused (RMTC 2016).
On amuch broader scale, the presence of zilpaterol
residues (as well as other β-adrenergic agonists) in
commercially produced food animals can have costly
trade implications. In the United States, where zilpa-
terol is approved for use only in cattle, maximum
allowable residues levels for zilpaterol in beef muscle
and liver are 10 and 12 ng g−1, respectively. Beef
tissues produced in the United States, but destined
for markets outside the US, must comply with zilpa-
terol tolerances of the importing country. For exam-
ple, the Korean MRL for zilpaterol in beef muscle is 1
ng g−1 and for the beef liver is 5 ng g−1 (MRL
Database 2019). Other countries, which strictly ban
zilpaterol, do not allow the import of any beef product
containing zilpaterol residues. Any detectable zilpa-
terol residue in non-beef meats, inside or outside the
US, is considered violative since zilpaterol is approved
only for use in beef animals. Regardless of the pre-
sence or absence of tolerance, exporters must ensure
thatmeat animal products comply with the importing
countries residue standards.
Sometimes such a guarantee has been problematic.
For example, in 2013 South Korea suspended a 22-
ton lot of beef imported from the US because of the
presence of zilpaterol residues and requested that the
importer “destroy or send back the meat” (Chung
and Waters 2013). The same year Taiwan detected
zilpaterol residues in beef imports on at least three
occasions (Hung et al. 2013) and suspended imports
from some U.S. beef producers. A 2013 Russian ban
on imports of U.S. meats because of the presence of β-
agonists was said to have cost the U.S. meat industry
$500 million in sales (Centner et al. 2014) and, as of
2017, the Chinese government required laboratory
reports for each lot of imported meat sampled in
addition to conducting residue testing during port
inspections (Fields et al. 2018).
Regardless of whether an enforcing agency repre-
sents international, national, state, county, or local
interests, those accused of causing a residue violation
often claim innocencewith respect to treating animals
with an illicit drug (CHRB 2014; RMTC 2016).
Numerous examples exist in which contaminated
feeds or foods, rather than illicit activity, was the
source of an illegal drug residue (Scheidegger 2013;
Bergin 2014; RMTC 2016). Trace level contamination
of food with β-agonists is a problem because expo-
sures to such food can cause positive drug tests in
consumers. For example, Guddat et al. (2012)
demonstrated that the illicit β-agonist clenbuterol
could be detected in the urine of 79% of individuals
returning from China, even though clenbuterol is
banned in China. It was presumed that clenbuterol
exposures originated from the consumption of con-
taminated meat. Horse feed, contaminated with zil-
paterol during manufacture, was widely
acknowledged to be the source of illegal zilpaterol
resides detected in at least 48 positive drug tests
(Anonymous 2013; Scheidegger 2013). Amore recent
example occurred when a horse trainer in Iowa faced
a $10,000 (US) fine and a year suspension from racing
when two horses under his care tested positive for
ractopamine. Although the ractopamine levels
detected were reported as “very low” and not suffi-
cient to cause a “performance-enhancing effect” the
burden of proof of innocence was on the trainer who
was responsible for legal and laboratory costs (RMTC
2016). The trainer ultimately proved that contami-
nated feed was the cause of positive urine and blood
tests. Of immediate concern to animal producers,
Gressler et al. (2016) demonstrated an average con-
centration of 36 ng g−1 of ractopamine in Brazilian
meat and bone meal, a widely used feed ingredient.
When such meat and bone meal was fed to swine,
residues were readily detected in urine, but not tissues
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(Aroeira et al. 2019) using a method having an LOQ
of 0.2 to 1 µg kg−1. Under “zero tolerance” rules any
detectable residue, no matter how low
a concentration, can be considered prima facie evi-
dence of illicit activity (HLSR 2018), depending upon
the regulatory authority. However, it has long been
recognized that the presence of trace quantities of the
drug within an animal matrix may be irrelevant with
respect to conveying physiologic action (Toutain
2010).
For leanness-enhancing β-agonists such as zil-
paterol, threshold doses and minimal lengths of
feeding are required for biological activity. For
example, dose–response studies have established
an optimal zilpaterol HCl dose for production
effects in cattle of 0.17 mg kg−1 body weight and
a minimal feeding period of 20 days (Intervet
2006). In sheep and goats, doses of zilpaterol for
growth performance are generally realized at
0.1 mg kg−1 body weight (Ríos Rincón et al.
2010; López-Carlos et al. 2014;) and are optimized
at 0.15 mg kg−1 body weight or above (Estrada-
Angulo et al. 2008; Mondagrón et al. 2010; Rodea
et al. 2016). Expressed on a dietary concentration
basis, zilpaterol is active in sheep at doses between
2.1 and 16.9 mg kg−1 of diet (dry matter basis;
Mondragón et al. 2010; López-Carlos et al. 2014).
The label dose of zilpaterol is 7.5 mg kg−1 fed to
cattle during the last 20 to 40 days on feed; in
sheep, zilpaterol may affect several growth or car-
cass endpoints when fed from 14 to 42 days
(López-Carlos et al. 2011).
Animals excrete relatively high concentrations
of zilpaterol in urine during times of active expo-
sures at production-enhancing doses. For exam-
ple, data in Table 4 confirm that urinary
concentrations of zilpaterol typically exceed 1,000
ng mL−1 (Stachel et al. 2003; Shelver and Smith
2006) and sometimes exceed 10,000 ng mL−1 in
urine from animals during zilpaterol exposure
(Shelver and Smith 2011). In the current study,
the greatest urinary zilpaterol concentrations were
200 to 400 ng mL−1 during active feeding at zilpa-
terol concentrations one-tenth the label dose.
Further reductions in urinary zilpaterol concen-
trations, commensurate with dose (1/100th and 1/
1000th the label dose), were measured during
animal exposures. Based on existing urinary data,
one could generally surmise that an animal excret-
ing over about 800 ng mL−1 of zilpaterol very
likely received a dose that approached, or was at,
a performance-enhancing dose. One might also
surmise that animals excreting less than 500
ng mL−1 of zilpaterol are in the withdrawal phase
of a growth-enhancing dose or were exposed to
a zilpaterol dose below that which causes produc-
tion effects. Other variables including frequency of
feeding, exposure duration, and time of urine col-
lection could influence absolute quantities of zil-
paterol excretion, but the order of magnitude of
residues collected at a given point will reflect the
magnitude of recent exposure.
Reported tissue residue data (Table 4) suggest
that animals dosed with production level doses of
zilpaterol will have liver or kidney residues above
20 ng g−1 if slaughtered with no withdrawal per-
iod. Livers and kidneys of animals dosed with
approximately 1/10th the label dose and slaugh-
tered with a zero-withdrawal period had residues
proportionally lower at 2 to 4 ng g−1 (Table 3).
Clearly, if liver or kidney residues are greater than
about 20 ng g−1 one can surmise that the animal
was exposed to growth-enhancing doses.
Conversely, one may surmise that liver or kidney
residues below about 10 ng g−1 are from animals
that were slaughtered during a withdrawal period
or were from animals which were not exposed to
a labeled dose. In the United States, zilpaterol is
labelled with a required 3-day withdrawal period.
This study clearly demonstrates that numerous
detection technologies, whether designed for
screening or quantitative purposes, can detect ani-
mal exposure to dietary zilpaterol levels far below
those required for growth-enhancing effects.
Concentrations of zilpaterol in urine or tissues
can be used to determine exposures but are less
useful for determining whether exposures were
purposeful or accidental. The usefulness of residue
data to assess guilt or intent with respect to caus-
ing growth-enhancing effects is not great unless
the magnitude of the residue concentration is
clearly sufficient to establish exposure to high
levels. In such cases, feed analyses should reveal
commensurate levels of zilpaterol.
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Table 4. Zilpaterol residues and excretion in beef, swine, sheep, and horses administered zilpaterol doses documented to have
caused production enhancing effects in cattle and sheep.
Dose Withdrawal Zilpaterol Residue
Amount Duration time Liver Muscle Kidney Urine
Species mg kg−1 bw d h ng g−1 ng g−1 ng g−1 ng mL−1 Reference
Cattle ~0.15 12 12 25 ± 8 4 ± 2 44 ± 29 Intervet 2006
24 10 ± 2 2 ± 0 11 ± 1
48 4 ± 4 ND 5 ± 5
96 ND ND ND
Veal Calf 0.15 2 0 1,400 Van Hoof et al. 2005
3 0 1,100
4 0 2,600
5 0 900
6 0 1450
7 0 1490
8 0 900
9 0 1050
10 0 –
11 0 800
12 0 2050
13 0 1500
Cattle 0.15 1 >1,000 Stachel et al. 2003
2 >1,000
3 >1,000
4 >1,000
7 >1,000
8 >1,000
9 >1,000
10 >1,000
11 >1,000
13 >1,000
14 0 >1,000
14 24 27 7 44 ~900
14 48 ~500
14 72 ~30
14 96 ~10
14 120 ~7
14 192 ~7
14 216 ~1
14 240 0.03 0.03 0.01 <1
Swine 0.15 25 24 8 3 8 189 Stachel et al. 2003
48 0.5 0.2 ND 10
96 0.2 0.2 0.3 6
120 ND 0.02 ND 2
Sheep 0.15 1 0 >1,000 Shelver and Smith 2006
3 0 >1,000
5 0 >1,000
8 0 >1,000
10 0 30.4 13.5 31.5 708 ± 861
10 24 195 ± 141
10 48 1.9 0.8 1.7 69 ± 51
10 72 53 ± 59
10 120 0.2 0.2 0.2 8 ± 15
10 168 1
10 216 0.1 - - <1
Horse 0.17 1 0 10,674 Shelver and Smith 2011
1 1,338
3 250
5 15
7 5
14 3
21 1
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